ARIAD Pharmaceuticals
| Company type | Public |
|---|---|
| Nasdaq: ARIA | |
| Industry | Pharmaceuticals, biotechnology |
| Founded | 1991 |
| Founder | Harvey Berger |
| Defunct | 2017 |
| Fate | Merged with Takeda Pharmaceuticals |
| Headquarters | Cambridge, Massachusetts, United States |
Key people | |
| Products | Ponatinib (FDA approved, trade name Iclusig) Ridaforolimus (FDA approved) Brigatinib (FDA approved) Rimiducid (Under development) AP32788 (Under development) |
| Revenue | US$118.8 million (2015) |
| US$−217.27 million (2015) | |
| US$−231.16 million (2015) | |
| Total assets | US$546.69 million (2015) |
Number of employees | 380 (2016) |
| Website | ariad |
ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients.
ARIAD’s most prominent drug discoveries include Iclusig, designed for patients with all forms of Philadelphia chromosome-positive [Ph+] chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) who are resistant to or unable to tolerate other tyrosine kinase inhibitors, and brigatinib, a lung cancer drug which has completed its registration trial in ALK fusion driven non-small cell lung cancer as of June 2016 and was approved in the U.S. in April 2017.
In January 2017, Takeda announced it would acquire ARIAD for $5.2 billion, expanding the company's oncology and hematology business. On February 16, 2017, Takeda Pharmaceuticals, Ltd. announced it had completed its acquisition of ARIAD and incorporated ARIAD into Takeda Oncology.